News Headlines

  1. FUJIFILM Biotechnologies Unveils ShunzymeX Precision Purification Technology 3/3/2026

    FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics.

  2. Cure Rare Disease And LGMD2L Foundation Announce Multi-Year Partnership To Develop Gene Therapy For Anoctamin 5-Related Disease 3/2/2026

    Cure Rare Disease (CRD), a non-profit biotechnology organization, today announced a landmark partnership with the LGMD2L Foundation.

  3. Congruence And Ono Pharma Expand Multi-Target Research Partnership With The Addition Of Two New Programs 3/2/2026

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") and Congruence Therapeutics today announced that they have expanded their existing multi-target research partnership through the execution of a new research collaboration for two additional programs.

  4. WuXi XDC Enters Strategic Collaboration With Earendil Labs On WuXiTecan-2 Payload-Linker Technology Platform 2/27/2026

    WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.

  5. Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas 2/26/2026

    Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. 

  6. Eckert & Ziegler Enters Partnership With Molecular Partners To Support Development Of Radio-DARPin Therapeutics 2/26/2026
  7. Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment 2/26/2026

    Quotient Sciences, a leading integrated CRDMO, announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

  8. SK bioscience, IDT Biologika And Vaxxas Selected For Next-Generation Influenza Vaccine Development Financed By The European Union 2/26/2026

    SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been selected for Phase 1 of a next-generation vaccine development initiative managed by the European Health and Digital Executive Agency (HaDEA) on behalf of the European Commission's Health Preparedness and Response Authority (HERA).

  9. ESTEVE CDMO Commences $15.5M Expansion Of Chicago Small Molecule API Facility 2/26/2026

    ESTEVE CDMO, the global pure-play CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, today announced that it had commenced a $15.5-M investment to enhance production capabilities and associated space at its newly acquired North American facility in Morton Grove, Illinois.

  10. Andelyn Biosciences To Apply the AAV Curator® Platform To Manufacture Clinical Grade AAV For Drake Rayden Foundation For The Treatment Of Nonketotic Hyperglycinemia 2/25/2026

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected by Drake Rayden Foundation to apply the AAV Curator® Platform to manufacture clinical grade AAV for the Treatment of Nonketotic Hyperglycinemia (NKH), a rare, inherited metabolic genetic disorder caused by a mutation in the GLDC gene.